DDInter255 DDInter233
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Busulfan {u} (Compound) downregulates {v} (Gene) GOLT1B
GOLT1B {u} (Gene) is downregulated by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Busulfan {u} (Compound) downregulates {v} (Gene) GOLT1B
GOLT1B {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Busulfan {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Busulfan {u} (Compound) downregulates {v} (Gene) ACAT2
ACAT2 {u} (Gene) is upregulated by {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Busulfan {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Busulfan {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Lovastatin
Lovastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Busulfan {u} (Compound) downregulates {v} (Gene) GOLT1B
GOLT1B {u} (Gene) is upregulated by {v} (Compound) Norethisterone
Norethisterone {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Busulfan {u} (Compound) downregulates {v} (Gene) ATP6V0B
ATP6V0B {u} (Gene) is downregulated by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Busulfan (Compound) downregulates GOLT1B (Gene) and GOLT1B (Gene) is downregulated by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Busulfan (Compound) downregulates GOLT1B (Gene) and GOLT1B (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Busulfan (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Busulfan (Compound) downregulates ACAT2 (Gene) and ACAT2 (Gene) is upregulated by Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Busulfan (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Busulfan (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Lovastatin (Compound) and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Busulfan (Compound) downregulates GOLT1B (Gene) and GOLT1B (Gene) is upregulated by Norethisterone (Compound) and Norethisterone may lead to a major life threatening interaction when taken with Brigatinib
Busulfan (Compound) downregulates ATP6V0B (Gene) and ATP6V0B (Gene) is downregulated by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Brigatinib